New Generation Triazoles: What Do They Offer and When Do We Need Them?  by Sorrell, T.C.
e iona
h
m
m
ﬁ
t
b
c
t
t
c
T
o
t
c
s
s
g
a
m
r
g
h
d
1
N
D
T
V
t
z
a
d
s
d
t
A
d
s
z
a
s
i
t
i
h
s
i
a
d
i
p
c
m
i
h
d
r
I
m
c
b
i
o
d
1
U
a
M
T
a
f
p
a
a
f
a
i
s
t
a
e
p
t
c
t
r
a
d
E
1
E
D
A
O
1
2
M
H
a
c12 13th Internat
elp deﬁne the optimal drug exposure associated with treat-
ent efﬁcacy. The analyses of data from experimental
odels with different antifungal drug classes have identi-
ed distinct pharmacodynamic characteristics. Results from
hese models have been useful for deﬁning the relationship
etween antifungal exposures and efﬁcacy. More recently
linical data has become available allowing similar inves-
igation. These results of these studies have been similar
o those from experimental models and have cemented the
linical signiﬁcance of these pharmacodynamic concepts.
he analyses have been shown to be helpful for the design
f antifungal dosing intervals, choice of optimal dose levels,
herapeutic drug monitoring, and the development of sus-
eptibility breakpoints. Most of these preclinical and clinical
tudies have targeted therapeutic efﬁcacy against Candida
pecies. More recent studies have also considered other fun-
al pathogens and have begun to investigate the role of
nifungal pharmacodynamics and drug resistance develop-
ent. Although there remain many unanswered questions
egarding antifungal pharmacodynamics, available data sug-
est usefulness in the application of pharmacodynamics to
elp guide antifungal therapy.
oi:10.1016/j.ijid.2008.05.071
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oriconazole and posaconazole are the latest triazole drugs
o be marketed. Voriconazole was developed from ﬂucona-
ole by substituting a ﬂuoropyrimidine ring for one of the
zole groups to enhance the spectrum (to include Can-
ida krusei, ﬂuconazole-resistant C. glabrata, Aspergillus
pp, some Fusarium strains, Scedosporium apiospermum and
imorphic fungi such as Histoplasma capsulatum) and adding
he a-methyl group to provide fungicidal activity against
spergillus spp. in particular. Posaconazole is structurally
erived from itraconazole, with ﬂuorine replacing chlorine
ubstituents in the phenyl ring and hydroxylation of the tria-
olone side chain. These modiﬁcations enhance the potency
nd spectrum of antifungal activity to include the additional
pecies covered by voriconazole with the exception of Fusar-
um and in addition, the zygomycetes.
Randomised controlled clinical trials (RCTs) have iden-
iﬁed that voriconazole is the treatment of choice for
nvasive aspergillosis in the immunosuppressed. Efﬁcacy
as been demonstrated in candidiasis (including against
mall numbers of ﬂuconazole-resistant Candida infections),
n fusariosis, cryptococcosis and infections where cheaper
gents such as ﬂuconazole would be preferred. The major
rawbacks to replacing ﬂuconazole with voriconazole are
ts cost, adverse effects including a small incidence of
hotosensitivity, signiﬁcant drug interactions, and pharma-
okinetic issues, which may be resolved by therapeutic drug
onitoring in some settings.
Posaconazole has been subject to RCTs of its use
n prophylaxis against fungal infections in recipients of
aematopoietic stem cell transplants where, despite some
d
m
r
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esign ﬂaws, it has performed better than the comparator
egimen, and in HIV-associated oro-pharyngeal candidiasis.
t has been used as salvage therapy in other settings. The
ain drawbacks to widespread use of posaconazole include
ost, the lack of an intravenous formulation, reduced
ioavailability in the absence of food and lack of RCTs of
ts therapeutic use.
Conﬁrmation of improved clinical outcomes from the use
f either agent in combination therapy is yet to be obtained.
oi:10.1016/j.ijid.2008.05.072
2.004
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he echinocandins, comprising caspofungin, micafungin and
nidulafungin, inhibit beta-(1,3)-glucan, Glucan is found in
ungal cell walls but not mammalian cells. As large highly
rotein bound molecules, none are orally bioavailable or
chieve levels in the CSF. The spectrum is consistent across
ll three agents with fungicidal activity against Candida, and
ungistatic activity against Aspergillus. The echinocandins
re not active against Cryptococcus,Scedosporium prolif-
cans or Zygomycetes. All are fungicidal against Candida
pecies although MIC90s vary slightly between agents with
he lowest MIC90s seen with anidulafungin, then micafungin,
nd caspofungin. However, it is not clear if these differ-
nces are clinically relevant. All have higher MIC90s for C.
arapsilosis, C. guilliermondii and C. lusitaniae compared
o other Candida spp. Although C. parapsilosis remains sus-
eptible despite a higher MIC90, resistance has emerged on
reatment. All may rarely cause histamine release with pru-
itis, rash and swelling. The differences between the agents
re shown in the table below:
oi:10.1016/j.ijid.2008.05.073
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FMD: Current Knowledge and Challenges for Malaysia
nd the Asia Paciﬁc Region
Background: Hand, foot and mouth disease (HFMD), espe-
ially that caused by EV71 is an important re-emerging
isease in the Asia Paciﬁc region, with the potential to cause
assive outbreaks that can last for many months, and with
elatively high complications rates, and deaths.
Methods: A review of the ﬁrst-hand experiences gained
uring the control of the four major HFMD outbreaks in
